Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Advisory Committees Find Benefits of Endo’s Opioid Drug Don’t Outweigh Risks

XTALKS VITALS NEWS

Opioid

Members from the Drug Safety and Risk Management (DSaRM), and Anesthetic and Analgesic Drug Products (AADP) advisory committees, voted 18 to eight against the opioid drug.

Share this!

March 16, 2017 | by Sarah Hand, M.Sc.

Advisory committees to the US Food and Drug Administration (FDA) have voted that the risk of abuse associated with Endo International’s opioid drug, Opana ER (oxymorphone hydrochloride extended release), outweighs its benefits. Members from the Drug Safety and Risk Management (DSaRM), and Anesthetic and Analgesic Drug Products (AADP) advisory committees, voted 18 to eight against the opioid drug.

The joint decision was made based on a number of factors, including the drug’s safety compared to other oxymorphone opioids, its risk-benefit profile, and the potential effect on patients if the drug were to be removed from the market. Despite one member of the committees abstaining from the vote, the majority of voters found that the benefits of Opana ER did not outweigh the risks.

According to the National Institute on Drug Abuse, 2.1 million people in the US suffered from prescription opioid abuse in 2012. The Centers for Disease Control and Prevention (CDC), reported that over 50 percent of 33,000 deaths attributed to opioid overdoses in 2015, were caused by abuse of prescription opioids.

In light of this opioid crisis, governments and regulators are cracking down on opioid drugs in an attempt to control the issue. Much of the blame has fallen upon drugmakers and distributers who supply opioid medications to hospitals, pharmacies and patients.



The FDA often follows the advice of these advisory committees, however they are not bound by law to do so. The FDA could decide to impart additional regulatory restrictions on the use of Opana ER, with the possibility that the opioid drug could be removed from the market altogether.

Currently, Opana ER is Endo’s highest-grossing pain management drug; in 2016, the drug brought in nearly $16 million in sales. For its part, Endo is committed to reduce abuse of the opioid medication by funding initiatives and implementing a pharmaceutical sterilization plan to reduce counterfeiting of the drug.

“Endo remains confident that the body of evidence established through clinical research demonstrates that Opana ER has a favorable risk-benefit profile when used as intended in appropriate patients,” said Dr. Matthew W. Davis, Senior Vice President, Research & Development, Branded Pharmaceuticals at Endo. “Our top priorities include patient safety and ensuring that patients with chronic pain have access to safe and effective therapeutic options. We plan to work collaboratively with the FDA as the Agency completes its evaluation of Opana ER, while advocating to preserve the important benefits of the medicine for patients.”


Keywords: FDA, Opioid, Drug Abuse


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Kite Pharma Secures FDA Approval for CAR-T Immunotherapy

October 20, 2017 - Kite Pharma’s Yescarta (axicabtagene ciloleucel) has become the second CAR-T immunotherapy to be approved in the US, with an indication in treating adult patients with relapsed or refractory large B-cell lymphoma.

Featured In: Biotech News


Fallopian Tubes Found to be Site of Origin for Most Ovarian Cancers

October 20, 2017 - This year, over 22,000 women will be diagnosed with ovarian cancer but a new study conducted by researchers at Perlmutter Cancer Center at NYU Langone Health suggests that most of these malignancies begin in another part of the reproductive system: the fallopian tubes.

Featured In: Life Science News


Food Companies are Looking for the Next Sriracha

October 19, 2017 - The Sriracha trend might be coming to an end and companies are looking for the next big hot sauce star to feature in their line-up.

Featured In: Food News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Five Reasons Why Toronto is Emerging as a Major Life Sciences Hub

REGISTER FOR THESE WEBINARS

Brexit – Separating Fact from Fiction


Evolving Best Practices for Working with Authors of Scientific Publications – Authorship and Beyond


Human Whole-Genome Sequencing in a New Era Defined by the Illumina® HiSeq X® and NovaSeq™ Platforms


Clinical Event Adjudication: Comprehensive and Efficient Dossier Review Using a Global On-Line Solution


Copyright © 2016-2017 Honeycomb Worldwide Inc.